Brooks Laboratories Ltd
NSE: BROOKS BSE: 533543
₹67.11
(-1.31%)
Mon, 02 Mar 2026, 05:01 pm
Market Cap1.99B
PE Ratio9.15
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KBrooks Laboratories Analysis
dividend
- Unable to calculate sustainability of dividends as Brooks Laboratories has not reported any payouts.
- Unable to evaluate Brooks Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Brooks Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Debt is covered by short term assets, assets are 1.2x debt.
- Brooks Laboratories's cash and other short term assets cover its long term commitments.
- Brooks Laboratories's level of debt (29.4%) compared to net worth is satisfactory (less than 40%).
- Brooks Laboratories's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- The level of debt compared to net worth has increased over the past 5 years (1.2% vs 29.4% today).
- High level of physical assets or inventory.
management
- The tenure for the Brooks Laboratories board of directors is about average.
- Rajesh's remuneration is lower than average for companies of similar size in India.
- Rajesh's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Brooks Laboratories management team is about average.
misc
- Brooks Laboratories is not covered by any analysts.
- Brooks Laboratories has significant price volatility in the past 3 months.
past
- Unable to compare Brooks Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Brooks Laboratories does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Brooks Laboratories has efficiently used its assets last year compared to the IN Life Sciences industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Brooks Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Brooks Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Brooks Laboratories's 1-year growth to the IN Life Sciences industry average as it is not currently profitable.
value
- Brooks Laboratories is good value based on assets compared to the IN Life Sciences industry average.
- NSEI:BROOKS is up 6.5% outperforming the Life Sciences industry which returned 2.6% over the past month.
- Brooks Laboratories is loss making, we can't compare its value to the IN Life Sciences industry average.
- Brooks Laboratories is loss making, we can't compare the value of its earnings to the India market.
- BROOKS underperformed the Life Sciences industry which returned 36.1% over the past year.
- BROOKS underperformed the Market in India which returned -14.5% over the past year.
- NSEI:BROOKS is up 6.5% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800